H
Loading...
Loading...
CDC PLACES (2023, crude) estimates 11.5% of adults in Providence have diagnosed diabetes — 0.5 points below the U.S. 12% figure. Census population 189,692. Rhode Island Medicare wound biologics: National Government Services (NGS) (JK). Hawk Medical is a national HCT/P 361 and wound-care distributor serving licensed Providence clinics — not a walk-in office.
Written for licensed providers. Reviewed by Joe Bradley, Founder & CEO. Content version 2026-09-18. Hawk Medical ships nationwide — this is not a Providence storefront.
Skin Substitute Therapy Products in Providence, RI for clinics & physicians. Skin substitute therapy for c… Compliance support & pricing — contact Hawk Medical.
Adult arthritis here is 18.8% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. CDC PLACES (2023, crude) estimates 11.5% of adults in Providence have diagnosed diabetes — 0.5 points below the U.S. 12% figure. Together those PLACES numbers are why a city under 250k still needs separate PRP and CTP protocols. skin substitute therapy inventory is national; utilization is JK-local.
National Skin Substitute Therapy Products notes (how the product actually works)CDC PLACES (2023, crude) estimates 11.5% of adults in Providence have diagnosed diabetes — 0.5 points below the U.S. 12% figure. Adult obesity in Providence is 34.4% (CDC PLACES 2023). That shows up in wound offloading and in joint-preservation volume — not as a slogan. Adult arthritis here is 18.8% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. Payer geography: JK / National Government Services (NGS), sibling states CT, MA, ME, NH, NY, VT. Rhode Island Department of Health is the public-health home. We will not mash those grains into a fake “demand score.”
If you already buy skin substitute therapy elsewhere, use this page as a check: homologous-use language, current National Government Services (NGS) article IDs, and PLACES 11.5% diabetes as the epidemiologic floor. If that is how you already practice, the catalog will fit.
CDC PLACES (2023, crude prevalence) estimates 11.5% of adults — 0.5 points below the U.S. 12% figure. Obesity is 34.4%; arthritis is 18.8%. That is place-level BRFSS modeling, not a clinic census and not a Providence trial.
No. PRP (autologous) and cellular/tissue products (allograft/skin substitutes) sit on different coding and coverage paths. National Government Services (NGS) LCDs for CTPs do not automatically cover PRP injections. Build separate protocols and fee tickets.
The allograft is used to perform the same basic function in the recipient as in the donor (FDA 361). Using umbilical or amniotic tissue as a marketed “stem cell cure” for unrelated conditions is outside that lane and is a Rhode Island compliance risk.
Body copy and schema dateModified follow a pinned content version date, not a daily timestamp. CDC and CMS figures are cited to the public reports named on the page. Recheck MAC LCDs before each utilization change — those move faster than a landing page.
If you operate in Rhode Island and another MAC state, say it on the first call. JK will not port 1:1. We would rather split utilization than watch a sister clinic copy Providence tickets into the wrong jurisdiction.
Contact us to learn how Hawk Medical supports practices in Providence, RI.
Hawk Medical is a national distributor. Joe Bradley’s clinic uses the same product classes. What is local for Providence is JK geography and published epidemiology — not a street address.
CDC PLACES 2023 crude rate for Providence — 0.5 points below the U.S. 12% figure. Planning input, not an outcomes claim.
Rhode Island Part B wound biologics follow this contractor (siblings: CT, MA, ME, NH, NY, VT). We train to the articles. We do not write coverage.
PLACES crude adult arthritis in Providence. Useful for joint-program math; still needs a diagnosis and privileging.
No Providence storefront. Joe Bradley is an active practice owner. skin substitute therapy stays in its regulatory lane — not “FDA-approved stem cell therapy.”
Experience the difference of working with a distributor who understands your practice because we operate one ourselves.